Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
Latest Information Update: 21 May 2024
At a glance
- Drugs Tafasitamab (Primary) ; Lenalidomide
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 15 May 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 15 May 2024 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 24 Feb 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.